Know Cancer

or
forgot password

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy


Phase 2
18 Years
N/A
Not Enrolling
Female
Ovarian Cancer, Cancer of the Fallopian Tube, Peritoneal Cancer

Thank you

Trial Information

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy


Inclusion Criteria:



histologically confirmed epithelial ovarian cancer, cancer of the fallopian tube or
peritoneum refractory to platinum- and taxane-based chemotherapy measurable or
non-measurable disease written informed consent aged 18 years or older Karnofsky
performance status > 60%

Exclusion Criteria:

complete bowel obstruction symptomatic brain metastases known hypersensitivity to
evaluated drugs inadequate kidney function inadequate hepatic function evidence of
clinically active interstitial lung disease history of congestive heart failure > NYHA 2

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerability

Principal Investigator

Uwe Wagner, Prof.Dr.

Investigator Role:

Principal Investigator

Investigator Affiliation:

AGO Study Group

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

AGO-OVAR 2.6

NCT ID:

NCT00189358

Start Date:

Completion Date:

Related Keywords:

  • Ovarian Cancer
  • Cancer of the Fallopian Tube
  • Peritoneal Cancer
  • cancer
  • cancer alternative therapies
  • ovarian cancer
  • tyrosine kinase inhibitor
  • Carcinoma
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Fallopian Tube Neoplasms
  • Neoplasms, Glandular and Epithelial

Name

Location